Crescent Biopharma
CBIO
58 hedge funds and large institutions have $286M invested in Crescent Biopharma in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
173.59% more ownership
Funds ownership: 0% → 173.59% (+174%)
112% more capital invested
Capital invested by funds: $135M → $286M (+$151M)
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
41% more funds holding
Funds holding: 41 → 58 (+17)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.6M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$21.4M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$19.1M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$17.3M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$5.36M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$3.25M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.38M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $42.5K | +$45.6K | +3,581 | +89,525% |
|
52
Citigroup
New York
| $7.39K | -$2.23K | -175 | -22% |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $4.85K | +$2.66K | +209 | +105% |
|
|
SS
54
SBI Securities
Tokyo,
Japan
| $806 | – | – | – |
|
55
Osaic Holdings
Scottsdale,
Arizona
| $308 | – | – | – |
|
56
Group One Trading
Chicago,
Illinois
| $47 | -$994 | -78 | -95% |
|
|
CC
57
Commodore Capital
New York
| – | -$5.36M | -450,829 | Closed |
|
|
FLSM
58
Frazier Life Sciences Management
Palo Alto,
California
| – | -$3.25M | -272,951 | Closed |
|
|
59
Adage Capital Partners
Boston,
Massachusetts
| – | -$2.38M | -200,005 | Closed |
|
|
SCM
60
Soleus Capital Management
Greenwich,
Connecticut
| – | -$2.38M | -200,000 | Closed |
|
61
Citadel Advisors
Miami,
Florida
| – | -$304K | -25,593 | Closed |
|
|
AAA
62
Affinity Asset Advisors
New York
| – | -$214K | -17,998 | Closed |
|
|
AW
63
Avion Wealth
The Woodlands,
Texas
| – | +$510 | +40 | New |
|
CBIO Hedge Fund Activity: Q4 2025 in Review
58 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2025, worth a combined $286M — up 112% from $135M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CBIO positions and 6 closed out — a net gain of 17 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $34.6M. The largest seller was Commodore Capital, exiting entirely with an estimated $5.36M sold.
- 58 institutional investors held Crescent Biopharma (CBIO) as of Q4 2025, up from 41 in Q3 2025.
- Funds reported $286M of Crescent Biopharma stock for Q4 2025, up 112% quarter-over-quarter.
- 23 funds opened new Crescent Biopharma positions in Q4 2025 and 6 closed out, a net change of +17 holders.
- The largest Crescent Biopharma buyer in Q4 2025 was Fidelity Investments, an estimated $34.6M added.
- The largest Crescent Biopharma seller in Q4 2025 was Commodore Capital, an estimated $5.36M sold.
Based on aggregated 13F filings for Q4 2025.